[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370929-105":59,"doc-detail-370929-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-new-era-in-oncology-clinical-insights-into-the-application-of-oncolytic-viruses-review","A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses - Review","","Cancer therapies often carry significant side effects, driving interest in biological approaches such as oncolytic viruses (OVs). The review traces early OV research from adenovirus to other viruses including HSV, reovirus, and measles, emphasizing safety and antitumor activity. OV cancer therapy is based on engineered viral infectivity and immunogenicity for selective tumor-cell targeting. Following FDA approval of HSV-based T-VEC for melanoma, clinical exploration has expanded across cancer types. Using clinical trial data from 2013–2024, the review examines OV classification, mechanisms, delivery strategies, genetic modifications, and summarizes key trials, including combinations with immune checkpoint inhibitors or established therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-new-era-in-oncology-clinical-insights-into-the-application-of-oncolytic-viruses-review/370929/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-new-era-in-oncology-clinical-insights-into-the-application-of-oncolytic-viruses-review/370929.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the central principle behind oncolytic virus (OV) cancer therapy?","Question",{"text":112,"@type":113},"OV therapy relies on engineering viruses to selectively infect tumor cells and exploit their viral infectivity and immunogenicity. Viral replication induces lysis and can trigger immune activation against tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which viruses were studied early in the development of OV therapies?",{"text":117,"@type":113},"Early investigations included adenovirus, followed by studies of other viruses such as herpes simplex virus (HSV), reovirus, and measles virus. These were evaluated for safety profiles and antitumor efficacy in humans.",{"name":119,"@type":110,"acceptedAnswer":120},"How has clinical interest in OVs expanded after regulatory approval?",{"text":121,"@type":113},"After FDA approval of HSV-based T-VEC for melanoma, attention increased toward exploring other viral platforms for treating various cancer types. Many OVs have progressed into multiple stages of clinical evaluation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370929,1790833732,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses  \nCancer Control Volume 32: 1-20 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10732748251382295](DOI: 10.1177/10732748251382295)  \n[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nS. M. Shahriar Alam, BSc 1,* 􀀁, Mashiat Tasnim, BSc1,*, Tasbir Amin, BSc 1 􀀁, and S. M. Bakhtiar Ul Islam, PhD 1 􀀁  \nAbstract  \nWhen considering treatment-related side effects, cancer therapies often present the most signiﬁcant severity. Given considerations of safety and efﬁcacy, there is a growing inclination towards biological therapeutic approaches, with Oncolytic Viruses (OVs) emerging as a prominent focus. Initial investigations into OVs commenced with Adenovirus, subsequently leading to the study of other viruses, including Herpes Simplex Virus (HSV), Reovirus, and measles virus, evaluating their potential safety proﬁles and antitumor efﬁcacy in human subjects. The fundamental principle underlying OV-based cancer therapy lies in harnessing viral infectivity and immunogenicity, which are engineered for selective targeting of tumor cells. Following the US Food and Drug Administration (FDA) approval of the HSV-based therapy (T-VEC) for Melanoma, interest in exploring other viral platforms for the potential treatment of various cancer types has notably expanded. A considerable number of OVs have progressed to various stages of clinical evaluation. This review provides an in-depth examination of OV classiﬁcation, mechanisms of action, delivery strategies, and crucial genetic modiﬁcations, furthermore summarizing data from pivotal trials to underscore the efﬁcacy and advancement of OVs from investigational modalities to clinical implementation. For the scope of this review, clinical trial data spanning the past 11 years (2013 to 2024) were accessed [from](from ClinicalTrials.gov)[ ClinicalTrials.gov](from ClinicalTrials.gov) and further categorized according to their ongoing clinical trial phases and their utilization in combination with Immune Checkpoint Inhibitors (ICI) or other established therapies. In summary, this work presents a comprehensive overview of recent developments within the ﬁeld of cancer therapy, speciﬁcally concerning Oncolytic Viruses.  \nPlain Language Summary  \nThis study explains how specially engineered viruses can safely kill cancer cells and help the immune system ﬁght tumors more effectively 4) Plain Language Summary: -This review explores the role of oncolytic viruses (OVs) in cancer therapy. It discusses how these viruses are engineered to target and destroy tumor cells while stimulating immune responses, with growing clinical success—especially when combined with other treatments like immunotherapy and chemotherapy.  \nKeywords  \noncolytic virus, immune-checkpoint inhibitor, clinical trial  \nReceived: May 20, 2025; revised: August 23, 2025; accepted: September 9, 2025.  \nIntroduction  \nDespite signiﬁcant medical advancements in the 21st century, cancer remains a leading cause of mortality and morbidity globally.1,2 Conventional treatments, primarily surgery, chemotherapy, and radiotherapy, often serve as short-term solutions associated with considerable side effects on the patient’s  \n1 Department of Biochemistry and Microbiology, North South University, Dhaka, Bangladesh  \n*These authors contributed equally to this work.  \nCorresponding Author:  \nS. M. Shahriar Alam, Department of Biochemistry and Microbiology, North South University, SAC822, Plot 15, Block B, Bashundhara, Dhaka 1229, Bangladesh.  \nEmail: [bakhtiar.islam@northsouth.edu](bakhtiar.islam@northsouth.edu)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses","cbCaihKFpZEOLxR1","https://ap.wps.com/l/cbCaihKFpZEOLxR1","pdf",1207163,"English","# Abstract\n## Plain Language Summary\n## Keywords\n# Introduction\n## Conventional cancer treatments and the shift toward biological therapies\n## Core mechanisms of oncolytic virus therapy\n## Historical context and clinical development","[{\"question\":\"What is the central principle behind oncolytic virus (OV) cancer therapy?\",\"answer\":\"OV therapy relies on engineering viruses to selectively infect tumor cells and exploit their viral infectivity and immunogenicity. Viral replication induces lysis and can trigger immune activation against tumors.\"},{\"question\":\"Which viruses were studied early in the development of OV therapies?\",\"answer\":\"Early investigations included adenovirus, followed by studies of other viruses such as herpes simplex virus (HSV), reovirus, and measles virus. These were evaluated for safety profiles and antitumor efficacy in humans.\"},{\"question\":\"How has clinical interest in OVs expanded after regulatory approval?\",\"answer\":\"After FDA approval of HSV-based T-VEC for melanoma, attention increased toward exploring other viral platforms for treating various cancer types. Many OVs have progressed into multiple stages of clinical evaluation.\"}]","A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses - Review | PDF",1790190847,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0237574d7613893b2fb8a2a6d14d052c.webp",983,1272,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75e2a93b720b57f349e232f104e35b46.webp",982,1270,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4599de5bc10195e30667948c4707c7c.webp",981,1269,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95bc5678403d3bf8b7e13da72cb72b80.webp",980,1268]